Developing the Peptide Platform for Pandemic Preparedeness (P4)
Intranasal Fusion Inhibition
Pandemic Ready Science
Thylacine Bio is advancing a nasal spray that blocks
Covid-19
Our lead candidate is a lipopeptide designed to prevent SARS-CoV-2 from entering host cells. Use of this antiviral protects against contraction and transmission of the disease.
Compared to other therapies like monoclonal antibodies, our nasal spray is inexpensive to produce with a long shelf-life and does not require refrigeration. It is also easily transportable and highly stable.
We block the critical first step of infection: fusion between the viral envelope and the host cell. As a result, our lead candidate has been effective across variants. It is positioned to be a powerful long-term tool to halt the spread of COVID in the United States and globally.
Vries, Rory D. de, Katharina S. Schmitz, Francesca T. Bovier, Camilla Predella, Jonathan Khao, Danny Noack, Bart L. Haagmans, Sander Herfst, Kyle N. Stearns, Jennifer Drew-Bear, Sudipta Biswas, Barry Rockx, Gaël McGill, N. Valerio Dorrello, Samuel H. Gellman, Christopher A. Alabi, Rik L. de Swart, Anne Moscona, Matteo Porotto. “Intranasal Fusion Inhibitory Lipopeptide Prevents Direct-Contact SARS-CoV-2 Transmission in Ferrets.” Science, February 17, 2021. https://doi.org/10.1126/science/abf489
In the News
